Reporting Manager
Adiumentum Capital Fund I LP
Symbol
ATRA
Shares outstanding
6,853,832 shares
Disclosed Ownership
1,370,081 shares
Ownership
20%
Form type
SCHEDULE 13D/A
Filing time
16 May 2025, 18:28:02 UTC
Date of event
14 May 2025

Quoteable Key Fact

"Adiumentum Capital Fund I LP disclosed 20% ownership in Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (ATRA) on 14 May 2025."

Quick Takeaways

  • Adiumentum Capital Fund I LP filed SCHEDULE 13D/A for Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (ATRA).
  • Disclosed ownership: 20%.
  • Date of event: 14 May 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 16 May 2025, 18:28.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Adiumentum Capital Fund I LP 20% 1,370,081 0 1,370,081 /s/ Gregory A. Ciongoli By: Adiumentum Capital Fund I GP, LLC, its general partner Name: Gregory A. Ciongoli, Title: Managing Member 0002023734
Adiumentum Capital Fund I GP LLC 20% 1,370,081 0 1,370,081 /s/ Gregory A. Ciongoli Name: Gregory A. Ciongoli, Title: Managing Member 0002023736
Gregory A. Ciongoli 20% 1,370,081 0 1,370,081 /s/ Gregory A. Ciongoli Name: Gregory A. Ciongoli 0002023732
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .